• Home
  • NEW DAY MEDICINE
  • 12 (74) 2024
  • 180 -12 (74) 2024 - Pulatova P.Kh. - CHRONIC KIDNEY DISEASE - DEFINITION OF CONCEPTS, PREVALENCE, CLINICAL AND PROGNOSTIC SIGNIFICANCE IN PATIENTS WITH MYOCARDIAL INFARCTION

180 -12 (74) 2024 - Pulatova P.Kh. - CHRONIC KIDNEY DISEASE - DEFINITION OF CONCEPTS, PREVALENCE, CLINICAL AND PROGNOSTIC SIGNIFICANCE IN PATIENTS WITH MYOCARDIAL INFARCTION

CHRONIC KIDNEY DISEASE - DEFINITION OF CONCEPTS, PREVALENCE, CLINICAL AND PROGNOSTIC SIGNIFICANCE IN PATIENTS WITH MYOCARDIAL INFARCTION

Pulatova P.Kh. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

In recent years, cardiorenal relationships have increasingly become a subject of discussion, both in the scientific and clinical spheres of modern medicine. This is due to the steady increase in the prevalence of not only cardiovascular pathology (hypertension, chronic heart failure, multifocal atherosclerosis, but also carbohydrate and lipid metabolism disorders, an increase in the frequency of detection of renal dysfunction and not primary renal pathology. In turn, the role of chronic kidney disease in worsening the prognosis in various groups of cardiac patients does not lose its relevance, continuing to be widely discussed. The interdependence of pathological processes in the cardiovascular system and kidneys, the bidirectional action of risk factors, both traditional (hypertension, diabetes, obesity, dyslipidemia, hyperglycemia) and “renal” (hyperhydration, anemia, systemic inflammation, hypercoagulation) and predicted adverse outcomes in such a relationship, allow us to consider the interaction of these systems as a cardiorenal continuum.

Key words: renal dysfunction, coronary heart disease, ischemic heart disease, myocardial infarction.

First page

939

Last page

944

For citation:Pulatova P.Kh. - CHRONIC KIDNEY DISEASE - DEFINITION OF CONCEPTS, PREVALENCE, CLINICAL AND PROGNOSTIC SIGNIFICANCE IN PATIENTS WITH MYOCARDIAL INFARCTION//New Day in Medicine 12(74)2024 939-944 https://https://newdayworldmedicine.com/en/new_day_medicine/12-74-2024

List of References

  1. Sahin, B. Risk factors of deaths related to cardiovascular diseases in World Health Organization (WHO) member countries /B. Sahin, G. Ilgun //Health Social Care in the Community. 2022;30(1):73-80.
  2. Артериальная гипертония в российской популяции в период пандемии COVID-19: гендерные различия в распространённости, лечении и его эффективности. Данные исследования ЭССЕ-РФ3 /Ю. А. Балабанова, О. М. Драпкина, В. А. Куценко [и др.] //Кардиоваскулярная терапия и профилактика. 2023;22(8):3785.
  3. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants /B. Zhou, R. M. Carrillo-Larco, G. Danaei [и др.] //The Lancet. 2021;398(10304):957-980.
  4. Аксенова А.В. Лечение больных артериальной гипертонией в реальной клинической практике в 2010-2020 гг. (по данным национального регистра артериальной гипертонии) /А. В. Аксенова, Е. В. Ощепкова, И. Е. Чазова //Терапевтический архив. 2022;94(1):9-17.
  5. Российское кардиологическое общество. Проект клинических рекомендаций «Артериальная гипертензия у взрослых» 2022: URL: https: //Scardio.ru/content/Guidelines/proj ect/KR_AG.pdf (дата обращения 01.05.2024). - Текст: электронный.
  6. 2018 ESC/ESH Guidelines for the management of arterial hypertension / B. Williams, G. Mancia, W. Spiering [и др.] //European Heart Journal. 2018;39(33):3021-3104.
  7. Чазова И.Е. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. / И.Е. Чазова, Ю.В. Жернакова //Системные гипертензии. 2019;16(1):6-31.
  8. Гипертонический криз - клиническая трактовка термина / Е.В. Крюков, А.Н. Фурсов, Н.П. Потехин [и др.] //Клиническая медицина. 2021;99(2):146-149.
  9. Риск развития сердечно-сосудистых осложнений у пациентов с частыми гипертоническими кризами. Предварительные результаты многоцентрового ретроспективного исследования случай-контроль ОСАДА. /И.П. Колос, И.Е. Чазова, С.Н. Терещенко, С.Н. Наконечников //Терапевтический архив. 2009; 9c.
  10. Medication adherence and blood pressure control: a scientific statement from the American Heart Association /N.K. Choudhry, I.M. Kronish, W. Vongpatanasin [и др.] //Hypertension. 2022;79(1):1-14.
  11. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Stu / J. D. Stanaway, A. Afshin, E. Gakidou [и др.] //The Lancet. 2018;392(10159):1923-1994.
  12. Wright J. Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease Results From the AASK Trial /J. Wright, T. Jackson //JAMA. 2002;288(19):2421.
  13. Stamler J. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data / J. Stamler, R. Stamler, J. D. Neaton //Archives of Internal Medicine. 1993;153(5):598-615.

    file

    download